Extract but serial postnatal examination in single individuals gives
The fetal hemoglobin of 10 infants has been examined serially from birth to several hundred days of age. In the normal child, the ratio of G y to chain alters from about 7:3 at birth to about 2:3 at 150-200 days. In children with abnormalities of hemoglobin synthesis, the ratio changes a. expected from data from adults with the particular abnormality. Thus, little change in ratio was shown by two Pthalassemia homozygotes, whereas two 0-thalassemia heterozygoteb showed the same behavior as a nonnal child; the latter behavior is expected from one of the two classes of Pthalassemia heterozygotes. A heterozygote from the G y A y class of hereditary persistence of fetal hemoglobin behaved much like a normal child, but two heterozygotes from the G y class showed the expected change from approximately 9:l at birth to 10:O postnatally. Two children with sickle cell anemia resembled a normal child in change of ratio whereas the third, not unexpectedly, did not show a change in ratio.
Speculation
The .mechanisms involved in the gradual change from y chain synthesis to and 6 chain synthesis are complex and ill defined. The results of analyses of the ratio between the products of the " y and A y structural genes in infants with distinct genetic disorders at birth and during the postnatal period underscore the complexity of the changeover. However, differences in the postnatal change in the G y to A y ratio in infants with an apparent identical condition may help to further define these mechanisms, and t o delineate the conditions involved.
The postnatal changeover from the production of hemoglobin F (Hb-F) t o hemoglobin A (Hb-A) takes a far more complex path than is superficially apparent. The nonallelic structural genes for the y chain of Hb-F (14), of which there may be four (5), appear to be nonsynchronously suppressed (1 I), with the result that the trace of Hb-F in the adult has a different heteroeeneitv than the Hb-F of the newborn child.
information about the behavior of regulatory mechanisms (1 1). Not only infants with abnormal Hb-F but also neonates with other abnormal conditions of various types have been studied in this way (1 1, 12). We have now been able to examine infants with thalassemia major and trait, with the G y type of the hereditary persistence of fetal hemoglobin (HPFH), with the G y A y type of HPFH, and with sickle cell anemia. Patients with thalassemia major or with sickle cell anemia usually are detected only when medical attention is required. Consequently, little is known about the status of such an individual at birth or about the onset of the diseaae. Present studies provide information about the status of such neonates and their progress, and also test speculations about how the y to A y ratio should change after birth.
MATERIALS AND METHODS

SOURCE O F SAMPLES
EDTA was used as anticoagulant in samples for hematologic examination, and larger samples for isolation of the hemoglobins were placed in EDTA or Alsever's solution.
HEMATOLOGIC DETERMINATIONS
Hemoglobin concentration, packed cell v6lume, and erythrocyte and reticulocyte counts were determined by standard methods (18) .
ANALYTICAL METHODS FOR HEMOGLOBIN COMPOSITION
Hemolysates were examined both by starch gel electrophoresis in Tris-EDTA-boric acid buffer at pH 9.0 (2) and by DEAE-Sephadex chromatography for analytic and isolative purposes (1, 4) . Hemoglobin F was determined by a procedure which uses the isoleucine content of chromatographically isolated Hb-F in its relation to leucine and phenylalanine as the basis for calculation (15) . These values are presented as percentage of FI1,.
Thus, in the newborn-child, the ratio of G y to A y chains (19) , CHEMICAL ANALYSIS O F Hb-F on the average, is 7:3 (16), whereas it is about 2:3 in the traces of Hb-F in the adult (12) . Examination of Hb-F from cord
The procedure described previously (14) was used to blood and adult blood provides the extremes in these ratios, determine the ratio of the two types of y chains in Hb-F. The 
POSTNATAL CHANGE IN HEMOGLOBIN
3 data are presented as the number of glycyl and alanyl residues in the carboxy-terminal yCB-3 peptide and are precise to f 0.05 residues (8) . The meaning of the data is given in Reference 19.
CASE HISTORIES
Hemat-gic data are presented in Table 1 .
THALASSEMIA MAJOR AND TRAIT
Family B. MB was born August 2, 1971 and weighed 3,120 g. At 42 days of age, she weighed 4,426 g and was 56.5 cm long; liver and spleen were not enlarged. At 77 days of age, the liver and spleen were detectable at the costal margin. Because the hemoglobin level had decreased to 6 g/100 ml, transfusion of MB was started on the 112th day. Since transfusion was begun, her hemoglobin has been maintained above 10.5 g/100 ml, and at 2 years of age she receives transfusions every 3 or 4 weeks. The s~l e e n and liver are minimallv enlarged. Ironchelating agents have not been given. ~rowth-and de;elopment have been normal.
JB, a 14-year-old sister, also has 0-thalassemia major. Her parents and two -other siblings have 0-thalassemia trait. The family is of Italian descent. Family K. CK was born October 30, 1971 and was first seen at the age of -109 days. At that time, the boy was well developed and well nourished with a liver and spleen that were both about 2 cm below the costal margin. Transfusions were begun a t the age of 132 days. He also has been maintained above 10.5 g/100 ml hemoglobin and at 2 years of age, he requires transfusions every 4-5 weeks. Like MB, spleen and liver are minimally enlarged, growth and development are normal, and iron chelating agents have not been given.
His parents are of Greek descent and have the typical stigmata of P-thalassemia trait.
Family N. TN was born December 9, 1970. Her mother was known t o have P-thalassemia trait, and the child has also developed these characteristics. She has had no significant illnesses that can be attributed to heterozygosity for Pthalassemia. This child is of Italian descent.
Family S. Data from this Negro girl (RS) have been described (12) and are presented again for comparison with those of TN.
HEREDITARY PERSISTENCE O F FETAL HEMOGLOBIN
Family A. JTA was born October 28, 1972 in Bombay. Her mother has the same type of HPFH that JTA has developed, but both are clinically normal. Although the father has n o t ' been examined, he probably has Pthalassemia. This conclusion arises from the fact that LTA, a 3-year-old sibling of JTA, is anemic, has mild hepatosplenomegaly, and requires occasional transfusions. LTA is believed to have both HPFH and Pthalassemia (1 7).
Family C. NOC was born December 24, 1972 in Bombay. dis mother and a 2-year-old sister both have the type of HPFH that he has developed and all of these individuals are clinically normal. His father has P-thalassemia (Hb-A2, 4.8%) and NOC's 3-year-old sibling has HPFH-0-thalassemi~ with expression like that of LTA of Family A.
Family Be. RBe was born January 19, 1970. Her mother, uncle, two aunts, and grandmother have the same kind of GyAy-type HPFH. This child has been studied repeatedly over the years and some of the data have been presented previously (lo), whereas information on her relatives (described as Family E ) has been given in an earlier publication (8) . Her clinical course has been uneventful. developed at the age of 2 months. She was admitted repeatedly for infection, and died 4 hr after her last admission on June 7, 1973 , of pneumococcal meningitis. Both parents were identified as Hb-S heterozygotes.
Family M. EM was born August 13, 1973 and weighed 3,110 g. The disease in this patient was diagnosed at birth. Growth and development were relatively normal, but anemia was noted at 3 months of age. At 6 months of age, the spleen was enlarged. The patient is in reasonable health, and attends the out-patient clinic regularly. Both parents are Hb-S heterozygotes.
Family W. W W was born March 4, 1972, weighed 3,140 g, and showed a relatively normal growth and development. However, severe anemia was noted at 6 months of age. The patient had a poor attendance at the clinic and died at home in March 1973 of "infection." The mother was identified as a Hb-S heterozygote.
RESULTS
Although none of the infants who were observed at birth had any physical abnormalities at that time, examination of the hemoglobin from the cord blood of homozygotes for Pthalassemia and sickle cell anemia showed clear abnormality. Thus, MB with a homozygous Pthalassemia, and LH, EM, and W W with sickle cell anemia had no Hb-A; indeed, MB had only Hb-F and a trace of Hb-A2 at birth and produced no other hemoglobins whereas the others all had Hb-S with Hb-A2 and Hb-F. On the other hand, the a5normalities in the other neonates, all of whom are heterozygotes, became apparent only in later samples but were suspected because of the known abnormality in one of the parents. Figure 1 depicts the chromatographic results of samples from MB with homozygous 0-thalassemia at birth and at 112 days, before transfusion. CK's hemoglobin composition at 109 days was virtually indistinguishable from that of MB at 112 days. Although MB showed little change in hemoglobin composition, anemia became progressively worse.
The other children, despite the variety of their conditions, showed the expected decline of Hb-F and increase of an adult SICKLE CELL ANEMIA (20) EFFLUENT (m1) Family H. LH was born November 16, 1971 and weighed 
it is significantly lower in NOC's mother and 2-year-old sister, namely 11% and 17%, respectively, but heterozygotes for this type of HPFH show considerable variation in level even within families (1 7). The Hb-F in RBe, the third infant with HPFH trait, at the age of about 500 days has reached the level frequently observed in her mother and other relatives, namely 25-30%. Only in RS, heterozygous for Pthalassemia, did the Hb-F decline to almost the adult level within a period of about a year; in the others, Hb-F is in higher percentage than in normal children at a comparable age (12) .
The chemical examination of Hb-F through the determination of the value for glycine in yCB-3 gave data concerning the ratio of the two types of y chain in these patients; the interpretation of these data is given in Reference 19. An average glycine value of 0.7 was observed in 108 normal newborn infants (16) . A comparable value was seen at birth in the newborn infants of this study with the exception of JTA and NOC, both with a HPFH heterozygosity, whose values of 0.88 and 0.86 were at the upper limit of the normal range and of RBe whose value of 0.67 was at the lower limit of the normal range. The data for glycine in yCB-3 of various postnatal samples ire recorded in Table 1 and are plotted in Figures 2 , 3 , ar~d 4 as a function of postnatal age together with the levels of Hb-F observed during the same periods. The initially high value in the cases with Gy type of HPFH (JTA and NOC) rises to 1.0 postnatally and that in the neonate with G y A y type of HPFH decreases only slightly. The value in the two Pthalassemia heterozygotes, TN and RS, as well as the two SS patients, LH and W W , declines to that in the traces of Hb-F in the adult. On the other hand, EM, another SS patient, has a constant value for glycine in yCB-3 and the two individuals with thalassemia major show a slight decrease.
DISCUSSION
The results of this investigation are in basic accord with those that were anticipated from previous information about Hb-F in these conditions. This discussion will consider each category of disease separately.
The effect of a Pthalassemia mutation is a reduction in the production of 0 chains and consequently of hemoglobin A.
The consequences in the heterozygote are minor but, in the homozygote, a severe anemia usually develops with attendant bone changes, organomegaly, failure to thrive, and often death in early childhood. Different variants of Pthalassemia exhibit a varying imbalance in chain synthesis (see Reference 3 for references). There is no doubt that MB znd CK suffer from the most severe type, the socalled 0 -thalassemia, without detectable production of 0 chains and inadequate compensatory production of y chains. Within 3 4 months after birth, they developed a severe anemia which required transfusion for survival. The chromatographic analyses for hemoglobin composition were important for evaluating the genetic condition in these infants who were potential homozygotes because their parents were heterozygotes. These analyses, although decisive in these neonates, cannot be used universally for the diagnosis of Pthalassemia major at birth because homozygous neonates with only a partial suppression of P chain production will have Hb-A and may not, therefore, be strikingly abnormal.
There is a slight but hardly significant decrease in glycine of yCB-3 in postnatal samples from MB. Although the yCB-3 of CK was first examined at the age of 109 days, the data at that age and later are almost identical with those of MB. who also has thalassemia major are comparable with data from many adults with thalassemia major (9). MB's parents have glycine values that approximate that in Hb-F of the normal adult. This is typical of one of the two classes that are observed with Pthalassemia heterozygotes (9, 13); in the other class, the glycine value approximates that in Hb-F of the newborn infant.
On the other hand, the heterozygotes, TN and RS, have a progressive postnatal decline in the value of glycine in yCB-3. The final value is much like that of the parents of MB and places them in the same class. If either of these heterozygotes had been in the other class, their glycine value would have been about 0.70-0.75 at birth and would have remained essentially constant in postnatal life.
HEREDITARY PERSISTENCE O F FETAL
HEMOGLOBIN (FIG. 3) The HF' FH condition may be subdivided into three major types: the G y type, the A y type, and the G y A y type in which, respectively, the Hb-F has only G y chains, only chains, or both (see Reference 3 for summary). Infants JTA and NOC belong obviously to the G y type: their Hb-F, which at birth contained both G y and A y chains, has only G' Y chains in the Hb-F that persists in adult life. Infant RBe belongs to the G-YAy type.
In the normal child, the activity of both G y and A y genes is suppressed postnatally, and their ratio of production is altered. In JTA and NOC, we observe the suppression of the G y and chain loci on the normal chromosome, whereas the suppression of y chain loci on the abnormal chromosome which has the HPFH determinant is less complete and does not involve one of the G y loci. As a result, the A y chain disappears from the Hb-F and the persistent Hb-F has only G y chains. The various classes of HPFH have been considered to result from deletions of 6,P, and one or more y loci (see Reference 9 for a detailed discussion). In these two children, the deletion would involve the 6, P, and A y loci. Because of the production TA and NOC have a G y type of HPFH trait and RB has a GyA7 type f HPFH trait. The data on CB with a hemoglobin C trait are from .eference 12. f y chains from the norm'al chromosome is suppressed ~lmost) completely and that from the abnormal is at most artly suppressed, the deletion must also involve one or more :gulatory factors. It appears that this factor which is still ~cated on the normal chromosome can suppress y chain roduction in cis but cannot control the G y chain production 1 trans on the abnormal chromosome. Regulatory factors in le complex of 6, P, and y loci are considered in detail in :eference 9.
Similar considerations are valid for the infant RBe with the yAy type of HPFH. The production of and G y chains .om the normal chromosome is suppressed (almost) comletely but and G y chain production from the abnormal hromosome continues because the deletion involves 6 and P lain structural loci and presumably no y chain structural loci. .gain it can be assumed that the deletion includes one or more :gulatory factors. Unexplained is the relatively high glycyl 3vel (0.53-0.60) which is observed in this infant and also in er relatives (8) . This level is significantly higher than the most ommon value of about 0.3-0.45 in the G y A y type of HPFH.
Further consideration of regulatory factors may be made on le basis of data from JTA's sibling LTA. LTA presumably has le G y type of HPFH and Pthalassernia and produces Hb-F 4th glycine of 0.8 1 and alanine of 2.18 in yCB-3 (1 7). When a ombination of Pthalassemia with the A y type of HPFH (10) r the G y A y type of HPFH (7) is present, the quantity of Ib-F is much increased over what would be expected if the ffects of the two genes were simply additive. It has been oncluded (7, 10) that the increased Hb-F is produced in cis to le P-thalassemia determinant. The same conclusion may be :ached from the data on LTA. The glycine value of 0.81 in is yCB-3 means that both G y and Ay chains are present. ecause the HPFH determinant produces only G y chains, the y chains must derive from the presumed Pthalassemia eterminant. The sample of hemoglobin from LTA that was xamined contained only a few percent of Hb-A which may ave been the residue of a prior transfusion. This suggests that $-thalassemia is present. It may also be calculated in the manner described previously (7, 10) that the Hb-F from this thalassemia is the kind that would have a glycine value of about 0.75 in yCB-3 (9, 13). Apparently, then, the HPFH determinant (presumably because of deletion of some regulatory factor) is able to stimulate production of Hb-F when P-thalassemia is in trans but not when a normal chromosome is in trans.
SICKLE CELL ANEMIA (FIG. 4) The percentage of Hb-F in individuals with sickle cell anemia may vary considerably and it is generally considered that higher amounts ameliorate the effects of the disease. In the study of Hb-F in sickle cell anemia (6), there is a tendency for the glycine in WB-3 to approximate the value of 0.4 for normal adults. However, a significant number of cases have values of about 0.7 as does the newborn child. Nevertheless, these groupings are not as distinct as in thalassemia (see above). These results are puzzling and would not be the anticipated result of the mutation of a structural gene as the cause of sickle cell anemia is considered to oe. However, this study of the three children with sickle cell anemia shows this very effect. The glycine value in yCB-3 of EM changes not at all from the newborn value, whereas that of LH and W W has' the expected decline. Although the percentage of Hb-F has remained higher in EM than in the others, there is no correlation between quantity of Hb-F and glycine value (6).
CONCLUDING DISCUSSION
These studies bear out the anticipated postnatal behaviors in the glycine value of yCB-3 in infants with an abnormality in hemoglobin synthesis. Thus, in 0-thalassemia homozygotes, glycine in yCB-3 has changed only slightly; it would not be expected to decrease below 0.6 and may approach this as the children mature. Both Pthalassemia heterozygotes have shown a decline to the adult level of glycine in yCB-3 and, therefore, are shown to be in that subclass of Sthalassemia heterozygotes (9, 13). In HPFH heterozygotes, likewise, the behavior follows the anticipated pattern; glycine in yCB-3, already high at birth in the G y type of HPFH, increases t o 1.0 whereas in the GyAy type, it decreases t o the adult level.
In sickle cell anemia, most adult cases have the adult level and two children exemplify this by levels which decrease t o this value. However, the glycine value in yCB-3 of one child has not decreased postnatally, and some adults have also had values similar t o those in the neonate.
